These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18989354)

  • 1. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
    Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
    Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
    Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
    Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model.
    Dharmapuri S; Aurisicchio L; Biondo A; Welsh N; Ciliberto G; La Monica N
    Hum Gene Ther; 2009 Jun; 20(6):589-97. PubMed ID: 19222350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.
    Quaglino E; Mastini C; Iezzi M; Forni G; Musiani P; Klapper LN; Hardy B; Cavallo F
    Vaccine; 2005 May; 23(25):3280-7. PubMed ID: 15837233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
    Conforti A; Cipriani B; Peruzzi D; Dharmapuri S; Kandimalla ER; Agrawal S; Mori F; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2010 Apr; 28(20):3522-30. PubMed ID: 20332048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
    Greiner JW; Zeytin H; Anver MR; Schlom J
    Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice.
    Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A
    Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
    Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
    Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
    Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
    Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
    Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
    Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.